Hillmen, Peter. “The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in relapsed/Refractory CLL”. Hematology Meeting Reports (formerly Haematologica Reports) 1, no. 2 (May 28, 2009). Accessed July 22, 2024. https://www.pagepress.org/journals/hmr/article/view/226.